Craver Josiah 4
4 · Sensei Biotherapeutics, Inc. · Filed Apr 14, 2026
Research Summary
AI-generated summary of this filing
Sensei Biotherapeutics (SNSE) PFO Josiah Craver Receives Award
What Happened
Josiah Craver, the Principal Financial Officer & Principal Accounting Officer (PFO & PAO) of Sensei Biotherapeutics (SNSE), received a derivative award of 80,000 shares on April 10, 2026. The grant shows an acquisition price of $0.00 at grant (typical for option awards); no cash changed hands at grant and this was not a sale.
Key Details
- Transaction date: April 10, 2026; Form 4 filed April 14, 2026 (within the two-business-day filing window for this transaction date).
- Grant: 80,000 shares (derivative award) recorded at $0.00 acquisition price.
- Shares owned after transaction: not specified in the provided filing excerpt.
- Footnote (vesting): 25% vests and becomes exercisable on April 10, 2027; remaining shares vest in 36 equal monthly installments thereafter, with full vesting on April 10, 2030, subject to continuous service.
- No indication this was an exercise or sale — it’s a grant/award (transaction code A).
Context
This was an option/award grant, common as executive compensation and not an immediate market purchase or sale. The $0.00 grant price indicates an award/option grant; if and when Craver exercises options in the future, exercising will typically require paying an exercise price (not shown here) and may trigger subsequent reporting (exercise or sale). Grants can be routine and do not by themselves signal a near-term market action.
Insider Transaction Report
- Award
Stock Option (right to buy)
[F1]2026-04-10+80,000→ 80,000 totalExercise: $29.89Exp: 2036-04-09→ Common Stock (80,000 underlying)
Footnotes (1)
- [F1]25% of the shares subject to the option vest and become exercisable on April 10, 2027, and the remaining shares vest and become exercisable in 36 equal monthly installments thereafter, such that the option is fully vested on the fourth anniversary of the date of grant, or April 10, 2030, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.